The Blog

NeuroCog Trials Awarded NIH Grant to Study MCI & Alzheimer’s

NeuroCog Trials Awarded NIH Grant to Validate Performance-based Measure of Functioning in MCI & Alzheimer’s Disease Innovative technology answers the call for improved functional capacity measurements in cognitive disorders Durham, North Carolina, October 30, 2017 — NeuroCog Trials, Inc. (NCT), the premiere global cognition and clinical assessment consulting and technology company, today announced it received…

Read More

CNS Network Chosen by Cognitive Research Corporation to Conduct Driving Simulation Crossover Study

GARDEN GROVE, Calif., October 10, 2017 — CNS Network, a leading clinical research center in Southern California, is pleased to announce that the company has been chosen by Cognitive Research Corporation to conduct a driving simulation cross-over study of the sedative effects of a muscle relaxant as compared to a different muscle relaxant and a…

Read More

Dr. Luca Pani Joins NeuroCog Trials

Experienced pharmacologist, clinical scientist and senior regulatory leader brings new capabilities and expertise to growing clinical trials technology and service provider DURHAM, NORTH CAROLINA, September 18, 2017 – NeuroCog Trials (NCT), a clinical technology and research services company dedicated to supporting global drug development, announces the addition of former AIFA Director General, Dr. Luca Pani,…

Read More

Planning a Driving Study for Your Compound?

Will the FDA require a driving study for your compound? Let us help you plan a program to evaluate driving impairment. Cognitive Research Corporation (CRC) is the exclusive pharmaceutical industry provider of the state-of-the art, standardized, and validated PC-based driving simulator, the CRCDS-MiniSim, developed in partnership with the University of Iowa National Advanced Driving Simulator….

Read More

Hassman Research Institute appoints Dr. Larry Ereshefsky CSO, Early Phase Development

Hassman Research Institute (HRI) announced that Dr. Larry Ereshefsky joined the company as chief scientific officer, Early Phase Development. Dr. Ereshefsky brings to HRI more than 40 years of drug discovery and development experience including leadership roles at University of Texas Health Science and Parexel. Dr. Ereshefsky will be responsible for leading HRI’s efforts and…

Read More

NeuroCog Trials at AAIC – Exclusive First Look

POWERFUL SOLUTIONS FOR CLINICAL TRIALS NeuroCog Trials, with Richard Keefe, Ph.D. and scientist staff, would love to meet with you during the Alzheimer’s Association International Conference (AAIC).  We have refined our cognitive and functional assessment tools, and we’re introducing a new iPad-based platform for all rating scales, including the ADAS-Cog and CDR. Please email jessica.griffiths@neurocogtrials.com…

Read More

FutureSearch Trials of Neurology Receives Clinical Research Site Award from Sponsor

Dr. John Hudson and the FutureSearch Trials of Neurology team received the following award announcement from a sponsor: “To recognize the value of clinical research sites as a partner in the clinical research process, (sponsor) is presenting a Clinical Research Site Award to selected sites. It is my great pleasure to inform you that FutureSearch…

Read More

Expertise in pain — meet at APS?

Our Alliance of multi-specialty sites and PIs have strong phase I-III pain and pain modeling trial experience. We hope that our metrics speak for themselves: We can assist in the early stages of protocol development, providing enrollment estimates, budget drafts, and study feedback. Click here to request details on our pain capabilities or to set…

Read More

Alliance Investigator Dr. Anand Mehta will be attending American Diabetes Association (ADA) 2017 in San Diego, CA, 6/10-6/12.

Please contact Jeanette Caruso if you’d like to meet and share updates, jeanette@alliancesites.com or 916-933-3023.

Read More

Hassman Research Institute – A New Option for Your Renal and Hepatic Impairment Studies

With 20+ years of research experience, Hassman Research Institute (HRI) understands patients’ needs and trial designs, and has the state-of-the-art facility to successfully execute your next trial. HRI’s track record on hep C and hepatic and renal impairment trials is excellent, with an over 100% enrollment and completion rate to goal. HRI is a full-time…

Read More
Page 1 of 712 »